Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 6, 2009, Pages 971-978

  Rong, Yi Ping ^a   Barr, Paul ^a   Yee, Vivien C ^a   Distelhorst, Clark W ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

ABT 737; Apoptosis; Bcl 2; BH4; Calcium; Inositol 1,4,5 trisphosphate receptor; IP3R; Peptide 2; TAT BH4

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; BH 3II; BH4 PEPTIDE; CALCINEURIN; CALCIUM; CALCIUM CHANNEL; CHELERYTHRINE; DEXAMETHASONE; ETOPOSIDE; GENASENCE; GOSSYPOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; ISOSORBIDE; OBATOCLAX; PAXILLIN; PEPTIDE 2; PROTEIN BCL 2; PROTEIN BCL 2 INHIBITOR; PROTEIN BCL XL; PROTEIN INHIBITOR; RAF PROTEIN; RAS PROTEIN; STAUROSPORINE; TAT BH4 PEPTIDE; TUNICAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

APOPTOSIS; CALCIUM SIGNALING; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HEPATITIS; HUMAN; LEUKEMIA CELL; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SPINAL CORD INJURY;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BCL-X PROTEIN; CALCIUM SIGNALING; CELL LINE, TUMOR; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 67349156098     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.10.015     Document Type: Review

References (100)

1. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
2. Reed J.C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111 (2008) 3322-3330
3. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev., Cancer 5 (2005) 876-885
4. Chao D.T., and Korsmeyer S.J. BCl-2 family: regulators of cell death. Annu. Rev. Immunol. 16 (1998) 395-419
5. Cory S., and Adams J.M. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat. Rev., Cancer 2 (2002) 647-656
6. Cory S., Huang D.C., and Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22 (2003) 8590-8607
7. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
8. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev., Cancer 8 (2008) 121-132
9. Rong Y., and Distelhorst C.W. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu. Rev. Physiol. 70 (2008) 73-91
10. Orrenius S., Zhivotovsky B., and Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev., Mol. Cell Biol. 4 (2003) 552-565
11. Joseph S.K., and Hajnoczky G. IP(3) receptors in cell survival and apoptosis: Ca(2+) release and beyond. Apoptosis 12 (2007) 951-968
12. Zhong F., Davis M.C., McColl K.S., and Distelhorst C.W. Bcl-2 differentially regulates Ca2+ signals according to the strength of T cell receptor activation. J. Cell Biol. 172 (2006) 127-137
13. Rong Y.P., Aromolaran A.S., Bultynck G., Zhong F., Li X., McColl K., Matsuyama S., Herlitze S., Roderick H.L., Bootman M.D., Mignery G.A., Parys J.B., De Smedt H., and Distelhorst C.W. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol. Cell 31 (2008) 255-265
14. Yin X.M., Oltvai Z.N., and Korsmeyer S.J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369 (1994) 321-323
15. Chittenden T., Harrington E.A., O'Connor R., Flemington C., Lutz R.J., Evan G.I., and Guild B.C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374 (1995) 733-736
16. Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., Nettesheim D., Chang B.S., Thompson C.B., Wong S.L., Ng S.L., and Fesik S.W. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381 (1996) 335-341
17. Petros A.M., Medek A., Nettesheim D.G., Kim D.H., Yoon H.S., Swift K., Matayoshi E.D., Oltersdorf T., and Fesik S.W. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3012-3017
18. Antonsson B., Conti F., Ciavatta A.M., Montessuit s., Lewis S., Martinou I., Bernasconi L., Bernard A., Mermod J.J., Mazzei G., Maundrell K., Gambale F., Sadoul R., and Martinou J.C. Inhibition of Bax channel-forming activity by Bcl-2. Science 277 (1997) 370-372
19. Desagher S., and Martinou J.C. Mitochondria as the central control point of apoptosis. Trends Cell. Biol. 10 (2000) 369-377
20. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2 (2002) 183-192
21. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., Ierino H., Lee E.F., Fairlie W.D., Bouillet P., Strasser A., Kluck R.M., Adams J.M., and Huang D.C. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007) 856-859
22. Galonek H.L., and Hardwick J.M. Upgrading the BCL-2 network. Nat. Cell Biol. 8 (2006) 1317-1319
23. Berridge M.J., Bootman M.D., and Lipp P. Calcium-a life and death signal. Nature 395 (1998) 645-648
24. Berridge M.J., Lipp P., and Bootman M.D. The versatility and universality of calcium signalling. Nat. Rev., Mol. Cell Biol. 1 (2000) 11-21
25. Hajnoczky G., Davies E., and Madesh M. Calcium signaling and apoptosis. Biochem. Biophys. Res. Commun. 304 (2003) 445-454
26. Pinton P., and Rizzuto R. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ. 13 (2006) 1409-1418
27. Chen R., Valencia I., Zhong F., McColl K.S., Roderick H.L., Bootman M.D., Berridge M.J., Conway S.J., Holmes A.B., Mignery G.A., Velez P., and Distelhorst C.W. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER. J. Cell Biol. 166 (2004) 193-203
28. Oakes S.A., Scorrano L., Opferman J.T., Bassik M.C., Nishino M., Pozzan T., and Korsmeyer S.J. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 105-110
29. White C., Li C., Yang J., Petrenko N.B., Madesh M., Thompson C.B., and Foskett J.K. The endoplasmic reticulum gateway to apoptosis by Bcl-Xl modulation of the InsP3R. Nat. Cell Biol. 7 (2005) 1021-1028
30. Xu L., Kong D., Zhu L., Zhu W., Andrews D.W., and Kuo T.H. Suppression of IP3-mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase 1. Mol. Cell. Biochem. 295 (2007) 153-165
31. Hanson C.J., Bootman M.D., Distelhorst C.W., Wojcikiewicz R.J., and Roderick H.L. Bcl-2 suppresses Ca(2+) release through inositol 1,4,5-trisphosphate receptors and inhibits Ca(2+) uptake by mitochondria without affecting ER calcium store content. Cell Calcium 44 (2008) 324-338
32. St. Clair E.G., Anderson S.J., and Oltvai Z.N. Bcl-2 counters apoptosis by bax heterodimerization-dependent and -independent mechanisms in the T-cell lineage. J. Biol. Chem. 272 (1997) 29347-29355
33. Huang D.C., Adams J.M., and Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 17 (1998) 1029-1039
34. Hunter J.J., Bond B.L., and Parslow T.G. Functional dissection of the human Bc12 protein: sequence requirements for inhibition of apoptosis. Mol. Cell. Biol. 16 (1996) 877-883
35. Hanada M., Aime-Sempe C., Sato T., and Reed J.C. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J. Biol. Chem. 270 (1995) 11962-11969
36. Lee L.C., Hunter J.J., Mujeeb A., Turck C., and Parslow T.G. Evidence for alpha-helical conformation of an essential N-terminal region in the human Bcl2 protein. J. Biol. Chem. 271 (1996) 23284-23288
37. Cheng E.H., Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., Ueno K., and Hardwick J.M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278 (1997) 1966-1968
38. Shibasaki F., Kondo E., Akagi T., and McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 386 (1997) 728-731
39. Srivastava R.K., Sasaki C.Y., Hardwick J.M., and Longo D.L. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fax ligand transcription. J. Exp. Med. 190 (1999) 253-265
40. Cameron A.M., Steiner J.P., Roskams A.J., Ali S.M., Ronnett G.V., and Snyder S.H. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. Cell 83 (1995) 463-472
41. Bultynck G., Vermassen E., Szlufcik K., De Smet P., Fissore R.A., Callewaert G., Missiaen L., De Smedt H., and Parys J.B. Calcineurin and intracellular Ca2+-release channels: regulation or association?. Biochem. Biophys. Res. Commun. 311 (2003) 1181-1193
42. Feske S., Okamura H., Hogan P.G., and Rao A. Ca2+/calcineurin signaling in cells of the immune system. Biochem. Biophys. Res. Commun. 311 (2003) 1117-1132
43. Neilson J.R., Winslow M.M., Hur E.M., and Crabtree G.R. Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity 20 (2004) 255-266
44. Erin N., and Billingsley M.L. Domoic acid enhances Bcl-2-calcineurin-inositol-1,4,5-trisphosphate receptor interactions and delayed neuronal death in rat brain slices. Brain Res. 1014 (2004) 45-52
45. Erin N., Lehman R.A.W., Boyer P.J., and Billingsley M.L. In vitro hypoxia and excitotoxicity in human brain induce calcineurin-Bcl-2 interactions. Neuroscience 117 (2003) 557-565
46. Shimizu S., Narita M., and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 (1999) 483-487
47. Malia T.J., and Wagner G. NMR structural investigation of the mitochondrial outer membrane protein VDAC and its interaction with antiapoptotic Bcl-xL. Biochemistry 46 (2007) 514-525
48. Hiller S., Garces R.G., Malia T.J., Orekhov V.Y., Colombini M., and Wagner G. Solution structure of the integral human membrane protein VDAC-1 in detergent micelles. Science 321 (2008) 1206-1210
49. Shimizu S., Konishi A., Kodama T., and Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3100-3105
50. Baines C.P., Kaiser R.A., Sheiko T., Craigen W.J., and Molkentin J.D. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol. 9 (2007) 550-555
51. Morrison D.K., and Cutler R.E. The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 9 (1997) 174-179
52. Wellbrock C., Karasarides M., and Marais R. The RAF proteins take centre stage. Nat. Rev., Mol. Cell Biol. 5 (2004) 875-885
53. Wang H.G., Rapp U.R., and Reed J.C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87 (1996) 629-638
54. Wang H.G., and Reed J.C. Bc1-2, Raf-1 and mitochondrial regulation of apoptosis. Biofactors 8 (1998) 13-16
55. Olivier R., Otter I., Monney L., Wartmann M., and Borner C. Bcl-2 does not require Raf kinase activity for its death-protective function. Biochem. J. 324 Pt 1 (1997) 75-83
56. Hall A. A biochemical function for ras-at last. Science 264 (1994) 1413-1414
57. Denis G.V., Yu Q., Ma P., Deeds L., Faller D.V., and Chen C.Y. Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J. Biol. Chem. 278 (2003) 5775-5785
58. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
59. Chen C.Y., Liou J., Forman L.W., and Faller D.V. Differential regulation of discrete apoptotic pathways by Ras. J. Biol. Chem. 273 (1998) 16700-16709
60. Gulbins E., Bissonnette R., Mahboubi A., Martin S., Nishioka W., Brunner T., Baier G., Baier-Bitterlich G., Byrd C., Lang F., et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 2 (1995) 341-351
61. Moriishi K., Huang D.C., Cory S., and Adams J.M. Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9683-9688
62. Conus S., Rosse T., and Borner C. Failure of Bcl-2 family members to interact with Apaf-1 in normal and apoptotic cells. Cell Death Differ. 7 (2000) 947-954
63. Schaller M.D. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20 (2001) 6459-6472
64. Meredith Jr. J.E., Fazeli B., and Schwartz M.A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell 4 (1993) 953-961
65. Santini M.T., Rainaldi G., and Indovina P.L. Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit. Rev. Oncol. Hematol. 36 (2000) 75-87
66. Ruoslahti E., and Reed J.C. Anchorage dependence, integrins, and apoptosis. Cell 77 (1994) 477-478
67. Sorenson C.M. Interaction of bcl-2 with paxillin through its BH4 domain is important during ureteric bud branching. J. Biol. Chem. 279 (2004) 11368-11374
68. Sorenson C.M., and Sheibani N. Focal adhesion kinase, paxillin, and bcl-2: analysis of expression, phosphorylation, and association during morphogenesis. Dev. Dyn. 215 (1999) 371-382
69. Schaller M.D. FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration?. J. Cell Biol. 166 (2004) 157-159
70. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274 (1996) 784-787
71. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., and Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274 (1996) 787-789
72. de Moissac D., Zheng H., and Kirshenbaum L.A. Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. J. Biol. Chem. 274 (1999) 29505-29509
73. Hour T.C., Chen L., and Lin J.K. Suppression of transcription factor NF-kappaB activity by Bcl-2 protein in NIH3T3 cells: implication of a novel NF-kappaB p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2. Eur. J. Cell Biol. 79 (2000) 121-129
74. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M., Wolff K., Eichler H.G., and Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4 (1998) 232-234
75. Klasa R.J., Gillum A.M., Klem R.E., and Frankel S.R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12 (2002) 193-213
76. O'Brien S., Moore J.O., Boyd T.E., Larratt L.M., Skotnicki A., Koziner B., Chanan-Khan A.A., Seymour J.F., Bociek R.G., Pavletic S., and Rai K.R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 25 (2007) 1114-1120
77. Bedikian A.Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., Pavlick A.C., DeConti R., Hersh E.M., Hersey P., Kirkwood J.M., and Haluska F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24 (2006) 4738-4745
78. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., and Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
79. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., Goulet D., Viallet J., Belec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R.W., Beauparlant P., and Shore G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19512-19517
80. Paoluzzi L., Gonen M., Gardner J.R., Mastrella J., Yang D., Holmlund J., Sorensen M., Leopold L., Manova K., Marcucci G., Heaney M.L., and O'Connor O.A. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111 (2008) 5350-5358
81. Wang J.L., Liu D., Zhang Z.J., Shan S., Han X., Srinivasula S.M., Croce C.M., Alnemri E.S., and Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7124-7129
82. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., and Yuan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 3 (2001) 173-182
83. Chan S.L., Lee M.C., Tan K.O., Yang L.K., Lee A.S., Flotow H., Fu N.Y., Butler M.S., Soejarto D.D., Buss A.D., and Yu V.C. Identification of chelerythrine as an inhibitor of BclXL function. J. Biol. Chem. 278 (2003) 20453-20456
84. Becattini B., Kitada S., Leone M., Monosov E., Chandler S., Zhai D., Kipps T.J., Reed J.C., and Pellecchia M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem. Biol. 11 (2004) 389-395
85. Sugioka R., Shimizu S., Funatsu T., Tamagawa H., Sawa Y., Kawakami T., and Tsujimoto Y. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 22 (2003) 8432-8440
86. Ono M., Sawa Y., Ryugo M., Alechine A.N., Shimizu S., Sugioka R., Tsujimoto Y., and Matsuda H. BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough anti-apoptotic mechanism in rat hearts. Eur. J. Cardio-thorac. Surg. 27 (2005) 117-121
87. Cantara S., Donnini S., Giachetti A., Thorpe P.E., and Ziche M. Exogenous BH4/Bcl-2 peptide reverts coronary endothelial cell apoptosis induced by oxidative stress. J. Vasc. Res. 41 (2004) 202-207
88. Klein D., Ribeiro M.M., Mendoza V., Jayaraman S., Kenyon N.S., Pileggi A., Molano R.D., Inverardi L., Ricordi C., and Pastori R.L. Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets. Biochem. Biophys. Res. Commun. 323 (2004) 473-478
89. Klein D., Mendoza V., Pileggi A., Molano R.D., Barbe-Tuana F.M., Inverardi L., Ricordi C., and Pastori R.L. Delivery of TAT/PTD-fused proteins/peptides to islets via pancreatic duct. Cell Transplant 14 (2005) 241-248
90. McConnell K.W., Muenzer J.T., Chang K.C., Davis C.G., McDunn J.E., Coopersmith C.M., Hilliard C.A., Hotchkiss R.S., Grigsby P.W., and Hunt C.R. Anti-apoptotic peptides protect against radiation-induced cell death. Biochem. Biophys. Res. Commun. 355 (2007) 501-507
91. Hotchkiss R.S., McConnell K.W., Bullok K., Davis C.G., Chang K.C., Schwulst S.J., Dunne J.C., Dietz G.P., Bahr M., McDunn J.E., Karl I.E., Wagner T.H., Cobb J.P., Coopersmith C.M., and Piwnica-Worms D. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J. Immunol. 176 (2006) 5471-5477
92. Cittelly D.M., Nesic O., Johnson K., Hulsebosch C., and Perez-Polo J.R. Detrimental effects of antiapoptotic treatments in spinal cord injury. Exp. Neurol. 210 (2008) 295-307
93. Ju K.L., Manley N.C., and Sapolsky R.M. Anti-apoptotic therapy with a Tat fusion protein protects against excitotoxic insults in vitro and in vivo. Exp. Neurol. 210 (2008) 602-607
94. Cheung K.H., Shineman D., Muller M., Cardenas C., Mei L., Yang J., Tomita T., Iwatsubo T., Lee V.M., and Foskett J.K. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 58 (2008) 871-883
95. Cantara S., Thorpe P.E., Ziche M., and Donnini S. TAT-BH4 counteracts Abeta toxicity on capillary endothelium. FEBS Lett. 581 (2007) 702-706
96. Patterson R.L., Boehning D., and Snyder S.H. Inositol 1,4,5-trisphosphate receptors as signal integrators. Annu. Rev. Biochem. 73 (2004) 437-465
97. Bezprozvanny I. The inositol 1,4,5-trisphosphate receptors. Cell Calcium 38 (2005) 261-272
98. Taylor C.W., da Fonseca P.C., and Morris E.P. IP(3) receptors: the search for structure. Trends Biochem. Sci. 29 (2004) 210-219
99. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. (1991) 946-950
100. Merritt E.A., and Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277 (1997) 505-524